KEYNOTE-564 is the first Phase 3 trial to demonstrate superior overall survival with adjuvant therapy compared to placebo in patients with RCC
Late-breaking OS results selected for the official.
Post-Surgery Immunotherapy Boosts Kidney Cancer Survival Rates miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
Credit: Pixabay/CC0 Public Domain For the first time in fifty years, results from a phase 3 randomized, placebo-controlled trial have shown an overall survi .